LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Search

Charles River Laboratories International Inc

Cerrado

SectorSalud

157.32 -2.31

Resumen

Variación precio

24h

Actual

Mínimo

157.32

Máximo

163.84

Métricas clave

By Trading Economics

Ingresos

2.9M

56M

Ventas

-27M

1B

BPA

2.43

Margen de beneficio

5.529

Empleados

18,700

EBITDA

-23M

198M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+45.8% upside

Dividendos

By Dow Jones

Próximas Ganancias

18 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-862M

7.9B

Apertura anterior

159.63

Cierre anterior

157.32

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

341 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 feb 2026, 23:44 UTC

Acciones populares

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17 feb 2026, 23:20 UTC

Ganancias

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17 feb 2026, 22:57 UTC

Ganancias

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17 feb 2026, 21:59 UTC

Ganancias

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17 feb 2026, 23:54 UTC

Charlas de Mercado

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17 feb 2026, 23:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 feb 2026, 23:54 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 feb 2026, 23:45 UTC

Charlas de Mercado

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17 feb 2026, 23:19 UTC

Ganancias

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 23:15 UTC

Ganancias

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 22:58 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17 feb 2026, 22:58 UTC

Adquisiciones, fusiones, absorciones

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17 feb 2026, 22:57 UTC

Adquisiciones, fusiones, absorciones

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17 feb 2026, 22:50 UTC

Adquisiciones, fusiones, absorciones

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17 feb 2026, 22:44 UTC

Ganancias

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 22:42 UTC

Ganancias

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17 feb 2026, 22:36 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17 feb 2026, 22:36 UTC

Ganancias

Santos Final Dividend 10.3 U.S. Cents/Security

17 feb 2026, 22:36 UTC

Ganancias

Santos FY Underlying Profit US$898 Million, Down 25%

17 feb 2026, 22:35 UTC

Ganancias

Santos FY Revenue US$4.94 Billion, Down 8%

17 feb 2026, 22:35 UTC

Ganancias

Correct: Santos FY Net Profit US$818 Million, Down 33%

17 feb 2026, 22:35 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17 feb 2026, 22:34 UTC

Ganancias

Santos FY Net Profit US$818 Billion, Down 33%

17 feb 2026, 22:02 UTC

Adquisiciones, fusiones, absorciones

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17 feb 2026, 21:50 UTC

Adquisiciones, fusiones, absorciones

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17 feb 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

17 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 feb 2026, 21:49 UTC

Adquisiciones, fusiones, absorciones

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17 feb 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17 feb 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Comparación entre iguales

Cambio de precio

Charles River Laboratories International Inc Esperado

Precio Objetivo

By TipRanks

45.8% repunte

Estimación a 12 meses

Media 235.25 USD  45.8%

Máximo 265 USD

Mínimo 190 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Charles River Laboratories International Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

8

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

117.16 / 144.77Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

341 / 351 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat